Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dichlorphenamide
Drug ID BADD_D00652
Description A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Indications and Usage For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
Marketing Status approved; investigational
ATC Code S01EC02
DrugBank ID DB01144
KEGG ID D00518
MeSH ID D004005
PubChem ID 3038
TTD Drug ID D0J4GO
NDC Product Code 72065-002; 59651-223; 13668-676; 71090-001; 73435-011; 72065-001; 58159-071
UNII VVJ6673MHY
Synonyms Dichlorphenamide | Dichlofenamide | Diclofenamid | Glauconide | Daranide
Chemical Information
Molecular Formula C6H6Cl2N2O4S2
CAS Registry Number 120-97-8
SMILES C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urine abnormality20.02.01.0130.000899%Not Available
Vertigo17.02.12.002; 04.04.01.0030.001176%
Vision blurred17.17.01.010; 06.02.06.0070.000646%
Visual impairment06.02.10.0130.000703%Not Available
Vocal cord paralysis22.04.01.002; 17.04.06.0020.000254%
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.000254%Not Available
Peripheral swelling02.05.04.015; 08.01.03.0530.001234%Not Available
Muscle fatigue15.05.03.0060.000392%Not Available
Muscle tightness15.05.03.0070.000588%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.001234%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000588%Not Available
Hyperphosphaturia20.02.01.025; 14.04.03.006--Not Available
Ear discomfort04.03.01.0050.000450%Not Available
Paranasal sinus discomfort22.12.03.0180.000392%Not Available
Musculoskeletal stiffness15.03.05.0270.001626%Not Available
Growth retardation05.03.02.007; 15.03.05.016; 14.03.02.0310.000115%
Affect lability19.04.01.0010.000450%Not Available
Cerebral disorder17.02.10.0170.000254%Not Available
Urine phosphorus increased13.11.01.047--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.001038%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.001430%
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.0050.000646%
Cardiac disorder02.11.01.0030.000703%Not Available
Limb discomfort15.03.04.0140.000784%Not Available
Mental disorder19.07.01.0020.000254%Not Available
Motor dysfunction17.01.02.031; 15.05.06.0060.000507%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.002467%
Disease recurrence08.01.03.0500.012255%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages